Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas

Brain Pathology

Volumn 23, Issue 5, 2013, Pages 558-564

  Venneti, Sriram ^a   Garimella, Mihir T ^b   Sullivan, Lisa M ^c   Martinez, Daniel ^c   Huse, Jason T ^a   Heguy, Adriana ^a   Santi, Mariarita ^c   Thompson, Craig B ^a   Judkins, Alexander R ^d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Dorseyville Middle School   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Epigenetics; EZH2; H3F3A mutations; H3K27me3; methylation; pediatric glioblastoma

Indexed keywords

HISTONE H3; HISTONE H3F3A; LYSINE; MUTANT PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; ASTROCYTOMA; BRAIN CANCER; CELL INFILTRATION; CHILD; CHILDHOOD CANCER; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; GLIOMA; HISTONE METHYLATION; HISTONE TRIMETHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHOCYTE; MALE; NEUROEPITHELIOMA; OLIGODENDROGLIOMA; PILOCYTIC ASTROCYTOMA; PROTEIN EXPRESSION; SCHOOL CHILD; WILD TYPE;

EPIGENETICS; EZH2; H3F3A MUTATIONS; H3K27ME3; METHYLATION; PEDIATRIC GLIOBLASTOMA;

ADOLESCENT; BRAIN NEOPLASMS; CHILD; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HISTONES; HUMANS; LYSINE; MALE; METHIONINE; MUTATION; NEUROGLIA; POLYCOMB REPRESSIVE COMPLEX 2;

EID: 84882273357     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/bpa.12042     Document Type: Article

References (36)

1. Akizu N, Estaras C, Guerrero L, Marti E, Martinez-Balbas MA, (2010) H3K27me3 regulates BMP activity in developing spinal cord. Development 137: 2915-2925.
2. Berger SL, (2007) The complex language of chromatin regulation during transcription. Nature 447: 407-412.
3. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, et al (2002) Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science 298: 1039-1043.
4. Chase A, Cross NC, (2011) Aberrations of EZH2 in cancer. Clin Cancer Res 17: 2613-2618.
5. Chi P, Allis CD, Wang GG, (2010) Covalent histone modifications- miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer 10: 457-469.
6. Crea F, Hurt EM, Farrar WL, (2010) Clinical significance of Polycomb gene expression in brain tumors. Mol Cancer 9: 265.
7. Dubuc AM, Remke M, Korshunov A, Northcott PA, Zhan SH, Mendez-Lago M, et al (2013) Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathol 125: 373-384.
8. Ederveen TH, Mandemaker IK, Logie C, (2011) The human histone H3 complement anno 2011. Biochim Biophys Acta 1809: 577-586.
9. Hagarman JA, Motley MP, Kristjansdottir K, Soloway PD, (2013) Coordinate regulation of DNA methylation and H3K27me3 in mouse embryonic stem cells. PLoS ONE 8: e53880.
10. Horbinski C, (2013) To BRAF or not to BRAF: is that even a question anymore? J Neuropathol Exp Neurol 72: 2-7.
11. Hou P, Liu D, Dong J, Xing M, (2012) The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle 11: 286-295.
12. Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, et al (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3: 1194-1203.
13. Karpinski P, Ramsey D, Grzebieniak Z, Sasiadek MM, Blin N, (2008) The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 6: 585-591.
14. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124: 439-447.
15. Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, et al (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100: 11606-11611.
16. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, et al (2012) IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483: 474-478.
17. Orlando V, (2003) Polycomb, epigenomes, and control of cell identity. Cell 112: 599-606.
18. Orzan F, Pellegatta S, Poliani PL, Pisati F, Caldera V, Menghi F, et al (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37: 381-394.
19. Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, et al (2012) Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS ONE 7: e47663.
20. Pellakuru LG, Iwata T, Gurel B, Schultz D, Hicks J, Bethel C, et al (2012) Global levels of H3K27me3 track with differentiation in vivo and are deregulated by MYC in prostate cancer. Am J Pathol 181: 560-569.
21. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al (2012) Novel mutations target distinct subgroups of medulloblastoma. Nature 488: 43-48.
22. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482: 226-231.
23. Shen X, Liu Y, Hsu YJ, Fujiwara Y, Kim J, Mao X, et al (2008) EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell 32: 491-502.
24. Shih AH, Abdel-Wahab O, Patel JP, Levine RL, (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12: 599-612.
25. Sievert AJ, Jackson EM, Gai XW, Hakonarson H, Judkins AR, Resnick AC, et al (2009) Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol 19: 449-458.
26. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
27. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22: 425-437.
28. Sullivan LM, Yankovich T, Le P, Martinez D, Santi M, Biegel JA, et al (2012) Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors. Am J Surg Pathol 36: 73-80.
29. Suva ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, et al (2009) EZH2 is essential for glioblastoma cancer stem cell maintenance. Cancer Res 69: 9211-9218.
30. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419: 624-629.
31. Vastenhouw NL, Schier AF, (2012) Bivalent histone modifications in early embryogenesis. Curr Opin Cell Biol 24: 374-386.
32. Venneti S, Le P, Martinez D, Xie SX, Sullivan LM, Rorke-Adams LB, et al (2011) Malignant rhabdoid tumors express stem cell factors, which relate to the expression of EZH2 and Id proteins. Am J Surg Pathol 35: 1463-1472.
33. Vrolijk H, Sloos W, Mesker W, Franken P, Fodde R, Morreau H, Tanke H, (2003) Automated acquisition of stained tissue microarrays for high-throughput evaluation of molecular targets. J Mol Diagn 5: 160-167.
34. Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho YJ, et al (2010) Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell 18: 316-328.
35. Wu G, Broniscer A, McEachron TA, Lu C, Paugh BS, Becksfort J, et al (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44: 251-253.
36. Zhang R, Wang R, Chang H, Wu F, Liu C, Deng D, Fan W, (2012) Downregulation of Ezh2 expression by RNA interference induces cell cycle arrest in the G0/G1 phase and apoptosis in U87 human glioma cells. Oncol Rep 28: 2278-2284.